Evidence map›Paper›PMID 40265927›Full record

ArticleAntimicrobial agents and chemotherapy2025

Studies

Inés Bleriot, Lucía Blasco, Patricia Fernández-Grela, Laura Fernández-García, Lucia Armán, Clara Ibarguren, Concha Ortiz-Cartagena, Antonio Barrio-Pujante, José Ramón Paño, Jesús Oteo-Iglesias and 1 more

Abstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Inés BleriotDepartamento de Microbiología-Hospital A Coruña (HUAC), Grupo de Microbiología Traslacional y Multidisciplinar (Micro-TM), A Coruña, Spain.ORCID 0000-0002-1846-4693
Lucía BlascoDepartamento de Microbiología-Hospital A Coruña (HUAC), Grupo de Microbiología Traslacional y Multidisciplinar (Micro-TM), A Coruña, Spain.ORCID 0000-0002-4039-4142
Patricia Fernández-GrelaDepartamento de Microbiología-Hospital A Coruña (HUAC), Grupo de Microbiología Traslacional y Multidisciplinar (Micro-TM), A Coruña, Spain.
Laura Fernández-GarcíaDepartamento de Microbiología-Hospital A Coruña (HUAC), Grupo de Microbiología Traslacional y Multidisciplinar (Micro-TM), A Coruña, Spain.
Lucia ArmánDepartamento de Microbiología-Hospital A Coruña (HUAC), Grupo de Microbiología Traslacional y Multidisciplinar (Micro-TM), A Coruña, Spain.
Clara IbargurenDepartamento de Microbiología-Hospital A Coruña (HUAC), Grupo de Microbiología Traslacional y Multidisciplinar (Micro-TM), A Coruña, Spain.
Concha Ortiz-CartagenaDepartamento de Microbiología-Hospital A Coruña (HUAC), Grupo de Microbiología Traslacional y Multidisciplinar (Micro-TM), A Coruña, Spain.
Antonio Barrio-PujanteDepartamento de Microbiología-Hospital A Coruña (HUAC), Grupo de Microbiología Traslacional y Multidisciplinar (Micro-TM), A Coruña, Spain.
José Ramón PañoHospital Clínico Universitario "Lozano Blesa", Instituto de Investigación Sanitaria Aragón, Zaragoza, Aragon, Spain.ORCID 0000-0002-9600-8116
Jesús Oteo-Iglesias *CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Community of Madrid, Spain.
María Tomás *Departamento de Microbiología-Hospital A Coruña (HUAC), Grupo de Microbiología Traslacional y Multidisciplinar (Micro-TM), A Coruña, Spain.ORCID 0000-0003-4501-0387

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The widespread incidence of antimicrobial resistance has created renewed interest in the use of alternative antimicrobial treatments such as phage therapy. Phages are viruses that infect bacteria and generally have a narrow bacteria host-range. Combining phages with antibiotics can prevent the emergence of bacterial resistance. The aim of the present study was to develop phage therapy medical products (PTMPs) targeting clinical isolates of carbapenem-producing

Indexed as

Anti-Bacterial AgentsBacteriophagesKlebsiella InfectionsKlebsiella pneumoniaePhage TherapyAnimalsHumansLarvaMeropenemMicrobial Sensitivity TestsMothsAnti-Bacterial AgentsMeropenemendotoxinsGalleria mellonellaKlebsiella pneumoniaephage-antibiotic synergyphage therapy medical products (PTMPs)

Identifiers

PMID40265927
PMCPMC12135510

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.